Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model

Urology

Volumn 76, Issue 5, 2010, Pages 1267.e1-1267.e6

  Horinaga, Minoru ^a   Fukuyama, Ryuichi ^b   Iida, Masahiro ^b   Yanaihara, Hitoshi ^b   Nakahira, Yoko ^b   Nonaka, Shoichi ^b   Deguchi, Nobuhiro ^b   Asakura, Hirotaka ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; KI 67 ANTIGEN; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; ORTHOTOPIC BLADDER CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 78149313075     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.03.028     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
2. J.T. Hsieh, C.P. Dinney, and L.W. Chung The potential role of gene therapy in the treatment of bladder cancer Urol Clin North Am 27 2000 103 113
3. A. Bohle, and S. Brandau Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer J Urol 170 2003 964 969
4. M.J. Moore, I.F. Tannock, and D.S. Ernst Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer J Clin Oncol 15 1997 3441 3445
5. G. Dalbagni, P. Russo, and J. Sheinfeld Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder J Clin Oncol 20 2002 3193 3198
6. R. Gunelli, E. Bercovich, and O. Nanni Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study Br J Cancer 97 2007 1499 1504
7. Y. Horiguchi, W.A. Larchian, and R. Kaplinsky Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model Gene Ther 7 2000 844 851
8. D.A. Jacob, M. Bahra, and J.M. Langrehr Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells J Gastroenterol Hepatol 22 2007 738 748
9. P.D. Vegt, J.A. Witjes, and W.P. Witjes A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder J Urol 153 1995 929 933
10. D.A. Tolley, M.K. Parmar, and K.M. Grigor The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up J Urol 155 1996 1233 1238
11. D.L. Lamm, D.R. Riggs, and C.L. Traynelis Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder J Urol 153 1995 1444 1450
12. A.B. Alexandroff, A.M. Jackson, and M.A. O'Donnell BCG immunotherapy of bladder cancer: 20 years on Lancet 353 1999 1689 1694
13. M. Brake, H. Loertzer, and R. Horsch Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer Urology 55 2000 673 678
14. P.J. Cozzi, D.F. Bajorin, and W. Tong Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs Clin Cancer Res 5 1999 2629 2637
15. M. Laufer, S. Ramalingam, and M.P. Schoenberg Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study J Clin Oncol 21 2003 697 703
16. R. Bartoletti, T. Cai, and M. Gacci Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study Urology 66 2005 726 731
17. A.K. Nowak, B.W. Robinson, and R.A. Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy Cancer Res 62 2002 2353 2358
18. H.J. Ko, Y.J. Kim, and Y.S. Kim A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model Cancer Res 67 2007 7477 7486
19. T.L. Ratliff Role of animal models in understanding intravesical therapy with Bacille Calmette-Guerin Clin Infect Dis 31 2000 106 108
20. C.W. Pan, Z.J. Shen, and G.Q. Ding The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study J Urol 179 2008 1307 1311
21. R.S. DiPaola, and E.C. Lattime Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy J Urol 178 2007 1840 1841
22. A. Sasaki, S. Kudoh, and K. Mori Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro? Urol Int 59 1997 142 148
23. L.A. Langford, C.S. Cooksley, and F. DeMonte Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas Hum Pathol 27 1996 350 354
24. T. Asakura, Y. Takano, and M. Iki Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer J Urol 158 1997 385 388
25. L. Santos, T. Amaro, and C. Costa Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification Int J Cancer 105 2003 267 272